Drug Detail

Information about Guadecitabine

Generic Name	Guadecitabine
IND	SGI-110
Brand Name (US)
Manufacturer	Astex Pharmaceuticals
Drug Type	Pyrimidyne
Delivery	Injection
Approval Status	Phase 3
Indications
Overall Strategy	Reverse hypermethylation
Strategy	Reverse global methylation deviator pattern
Drug Category	SDH-directed

Guadecitabine was rationally designed to prolong the exposure of tumor cells to the active moiety, decitabine, ensuring greater uptake of decitabine into the DNA of rapidly dividing cancer cells.

Links
	Astex pipeline description

	YouTube video explaining Guadecitabine mechanism of action

Trials of this drug
	A Phase II Trial of the DNA Methyl Transferase Inhibitor, Guadecitabine (SGI-110), In Children And Adults With Wild Type GIST, Pheochromocytoma And Paraganglioma Associated With Succinate Dehydrogenase Deficiency And HLRCC-Associated Kidney Cancer

Trial results
	Clinical Cancer Research January, 2023: "A Phase II Trial of Guadecitabine in Children and Adults with SDH-Deficient GIST, Pheochromocytoma, Paraganglioma, and HLRCC-associated Renal Cell Carcinoma"

Search for this drug/combination in:

ClinicalTrials.gov